CC BY-NC-ND 4.0 · Thromb Haemost 2017; 117(07): 1326-1337
DOI: 10.1160/TH16-10-0793
Coagulation and Fibrinolysis
Schattauer GmbH

The management of acute venous thromboembolism in clinical practice

Results from the European PREFER in VTE Registry
Alexander T. Cohen
1  Guys and St Thomas’ Hospitals NHS Foundation Trust, King’s College, London, UK
,
Anselm K. Gitt
2  Herzzentrum Ludwigshafen Med. Klinik B, Ludwigshafen, Germany
,
Rupert Bauersachs
3  Klinikum Darmstadt GmbH, Darmstadt, Germany
4  Center of Thrombosis and Haemostasis, University of Mainz, Mainz, Germany
,
Eva-Maria Fronk
5  Daiichi Sankyo Europe GmbH, Munich, Germany
,
Petra Laeis
5  Daiichi Sankyo Europe GmbH, Munich, Germany
,
Patrick Mismetti
6  CHU Saint-Etienne Hopital Nord, Saint Etienne Cedex 2, France
,
Manuel Monreal
7  Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
,
Stefan N. Willich
8  Charité – Universitätsmedizin Berlin, Germany
,
Peter Bramlage
9  Institute for Pharmacology and Preventive Medicine, Mahlow, Germany
,
Giancarlo Agnelli
10  University of Perugia, Santa Maria della Misericordia Hospital, Perugia, Italy
,
the PREFER in VTE Scientific Steering Committee and the PREFER in VTE Investigators› Author Affiliations
Financial Support:This study was funded by Daiichi Sankyo Europe GmbH, Munich, Germany.
Further Information

Publication History

Received: 18 October 2016

Accepted after major revision: 22 March 2017

Publication Date:
28 November 2017 (online)

Summary

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0% were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5%). The diagnosis was deep-vein thrombosis (DVT) in 59.5% and pulmonary embolism (PE) in 40.5%. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5%), hypertension (42.3%) and dyslipidaemia (21.1%). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2%), almost half received a vitamin K antagonist (48.7%) and nearly a quarter received a DOAC (24.5%). Almost a quarter of all presentations were for recurrent VTE, with >80% of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes.

Author contributions

All authors have contributed to the design of the registry and/or the preparation of the manuscript. EMF was responsible for the analysis of data. ATC and PB drafted the first version of the manuscript and the remaining authors made substantial revisions to the manuscript. All authors have approved the version to be published. Apart from the selection of the countries, all design aspects were decided by the scientific Steering Committee and executed by independent Contract Research organizations.